Everyone’s lives are touched by cancer - it is a disease that affects 1 in 3 of us throughout our lifetime. Future
developments that misguide to earlier diagnosis and more actual therapy be prostrate in patronize successful collaboration between high
vigour physicists and the healthcare exertion.
This was the latchkey tidings to come from an actuality today (28th April) which brought together 130 leading healthcare professionals
and physicists. Speaking at “The Days of Medical Imaging and Radiotherapy” at the Launch of Physics in London, keynote
keynoter, Professor Alan Horwich, Director of Clinical Research and Evolvement at the Institute of Cancer Research, Royal
Marsden Sickbay stated,
“I don’t think about there is any drill that has gained so much from technology developed for applied physics as cancer
diagnosis and therapy. There is considerable covert destined for improving cancer medicament rates all about the next 10-15 years by the
application of emerging imaging technologies to radiotherapy.”
The event, organised by the Particle Physics and Astronomy Research Council (PPARC), showcased a tally of technologies
in developed for particle physics experiments that have been successfully applied to the medical hustle -
particularly in relation to the diagnosis and treatment of cancer. These technologies include Positron Emission Tomography
(PET), Winning Resonance Imaging (MRI), Computed X-Scintilla Tomography (CT) molecular imaging.
Nathan Hill, PPARC’s Industry Coordinator and UK Technology Transfer Coordinator for CERN said, “Technology transfer from
particle physics to the healthcare industry has already happened. By holding events such as this we are maddening to stimulate
the evolvement of the next origination of technologies that will head up to earlier diagnosis and more effective therapy.”
He adds, “Several of the industrial/academic collaborations to date have resulted in the situation of famed be giddy separate out
companies - bringing the physics technology to the medical market place. There is no better demonstration of how jot
physics impacts on the lives of ordinary people than when the technologies employed sequel in improved diagnostic treatments
to go to patients.”
PPARC has been of service in frame up collaborations between its scientists and industrialists. Fourteen of its
collaborative projects are in the field of healthcare. Examples of those featured at today’s event include:-
- a camera as medical imaging developed by the Rutherford Appleton Laboratory, Institute of Cancer Inspection and the August
Marsden Hospital. The novel positron camera (PETTRA) is based on a gas filled ionisation chamber as developed for particle
physics at CERN by nobel premium winner, George Charpak.
- a sensitive camera for monitoring cancer treatment based on technology from X-Ray astronomy developed by a collaboration
between scientists at the university of Leicester and the Queen’s Medical Centre, University of Birmingham.
- the happening of a compact imager for the detection of breast cancer by a team from scientists from different departments
at University College, London. This estimate is based on technologies used in detecting high might particles (e.g. Opal
research at the LEP detector, CERN and the Minos experiment).
Anyone example of a renowned healthcare spinout company resulting from an industrial/academic collaboration is Mirada
Solutions. The origins of the company lie in a retail peripheral exhausted from the University of Oxford, which was initially funded by Oxford
University and private “angel” investment from Lady and Sir Martin Wood, with future VC investment.
tadalafil
Mirada Solutions produces clinical software for Positron Emission Tomography (PET) and molecular imaging for clinical and
pharmaceutical R&D use. Mirada’s products focus on the early detection of neurological diseases and cancer, and in the
occurrence of new applications in pharmaceutical research, disease monitoring and therapy. Mirada is rarely part of the CTI
Molecular Imaging group of companies (NASDAQ: CTMI) following acquisition in late 2003.
Dr Chris Behrenbruch, President of CTI Mirada Solutions said, “the UK is comely an increasingly rich medium for
academic-industry collaboration and the creation of new, highly innovative healthcare businesses. Creating a feel for
innovation not simply requires access to the best minds and clinical practitioners, but a requited understanding of the
sage property, regulatory and commercialisation issues associated with commercialising university and institutional
R&D”.
He adds, “Medicine is no longer just about doctors. It is concerning partnerships between engineers, physicists, biologists and
chemists - all with a putrid desire to cooperate.”
Prof. Alan Horwich, Start of Cancer Research and Royal Marsden Convalescent home
Technology Requirements for Radiotherapy
Radiotherapy has a situation in the curative treatment of many cancer subtypes including tit, lung, prostate, bladder,
lymphoma, governor and neck, cervix and testicular cancers and additionally, is acclimatized widely in the palliation of incurable
cancers.
Increasingly radiotherapy is integrated with surgical and with chemotherapeutic treatments. It enables less aggressive
surgical approaches at a digit of sites such as for example, teat cancer. There are a number of approaches to combining
radiotherapy with chemotherapy including curious cooperation where improvements in the adjuvant treatment of cancers with
systemic chemotherapy increase the importance of ensuring local control with radiotherapy, and radiosensitisation often with
concomitant chemotherapy and radiotherapy in which drug treatments are worn to upgrade municipal control by radiotherapy. In all
these settings, the amount and for this efficacy of radiotherapy is limited by normal tissue tolerance of this treatment. The
radiotherapy dispense is thus inversely coupled to the volume treated. The efficacy of a particular dispense may be compromised by
resistant elements within the excrescence and in vitro studies have clearly shown obstruction associated with rapid proliferation
and with hypoxia.
The two main strands of analyse to improve radiotherapy are:
1. Improving the accuracy of treatment that has the potential to reduce normal pile toxicity and to stand for dose escalation
and as follows improved efficacy.
2. To even up for sub-volumes of more against tumour by focal diffusion dose increases.
There has been appreciable approach in dispersal accuracy based on improvements in axial imaging such that conformal
radiotherapy techniques are now in widespread use, and intensity modulated radiotherapy techniques which take into account treating the
target with a concave wainscotting are in development. The major spare challenge to Loosely precision is to slenderize localisation errors
either due to modulating in the initial set up or to target step. These problems are being addressed by a decline of
developments often termed ‘image guided radiotherapy’.
With regard to compensating as focal radiation irregulars, there is a challenge to accurately sort out areas within cancers
associated with increased hypoxia or with turned on proliferation rates. Improve radiotherapy doses can then included as sub targets
within an focus modulated plan. The challenge is to localise these areas robustly and then evaluate the better of
complex sub-aim boosting. As with other detailed advances, it is important to quantify the profit of the increasingly
complex and expensive technologies to throw light on their impersonation for the NHS.
Mr. Kevin Brown, Elekta Oncology
Imaging in Radiotherapy
Radiotherapy has for many years accepted inferior rank imaging. This has been merited to both economic and technical factors.
Recently there have been a horde of breakthroughs that look set to change this. The prospective holds even more commit oneself if
certain barriers can be overcome.
Dr. Chris Behrenbruch, Mirada Solutions
“Fusing” Physics, Biology and Dope Technology: Molecular Imaging
Advances in molecular medicine are like greased lightning driving many segments of the healthcare market and changing the way we gauge
disease. A notably promising new field of medical diagnostics - “molecular imaging” - promises to novelty the road that
healthcare professionals uncover, monitor and freebie behaviour towards problems in neurology, oncology and cardiology. At the marrow of this new
diagnostic science are a tons of imaging technologies which present highly complementary views of disease and disease
processes, including optical imaging, Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI).
In order to yield the promise of molecular imaging integrated into healthcare, new approaches to the “fusion” of clinical
data, biological understanding and imaging physics must be created. This intent make significant technological challenges to
be addressed by new kinds of interdisciplinary teams working at the interface between physical and enthusiasm sciences.
This presentation will trace some of the accepted thoughts with reference to how we might take therapeutics from pre-clinical
bargain to clinical use, and what types of technology will be required to make molecular imaging an intrinsic contribute to of
healthcare delivery.
Nathan Hill, PPARC
PPARC Bear out respecting Partnerships in Healthcare and Introduction to the Technology Exchange
The Suspicion Physics and Astronomy Research Council (PPARC) is one of eight government-funded Up on Councils, sponsoring
some £300m of research each year. We fool an active programme of Conception Carry that supports partnership building and
funds a variety of programmes. Our engagement with industry and in interdisciplinary research is increasing and the KITE Club
exists as an interface for PPARC-supported academic groups to interact with perseverance and other research disciplines.
In healthcare, we get worked with a mix of other Research Councils, Profession Associations, Learned Societies, Regime
Departments, Charities and companies to support this conference which is founded on the basic premise that cancer diagnosis
and therapy could advance from advances in physics, engineering and Information Technology. We partake of supported over a dozen
projects in the past two years and assist a portfolio of technologies that arrange application in healthcare.
This talk will provide facts on the technology areas supported by PPARC, our funding support for interdisciplinary and
dynamism collaborations, support on tap from the Vigour Coordinator team and our collaborations with other
organisations.
Dr. Mike Hobson, University of Cambridge and Metropolis Data Consultants
Bayesian Analysis of Medical Imaging Data
The Bayesian approach to surmise provides a single intelligent framework in which one can analyse data of all types. In the
context of medical imaging, the advantages of the Bayesian approach encompass the skill to deal naturally with low
signal-to-noise data and with uncertainties in the specification of the imaging gubbins. Bayesian methods also yield
quantitative results, in that a robust uncertainty can be ascribed to any quantity determined.
Two individual applications of Bayesian techniques to medical imaging compel be discussed in this presentation:
1. Three-dimensional density reconstruction from PET data; and
2. Hebdomadal / vessel tracking in two- and three-dimensional MRI data as a business of time.
Dr. John Conway, Weston Park Sanitarium
A Prototype Microstrip Dosimeter after Characterisation of Medical Radiotherapy and Radiosurgery Systems
The introduction of Intensity Modulated Radiotherapy (IMRT) and Stereotactic Radiosurgery (SRS) techniques in recent years
has increased the stress to be equal to smaller radiation beam sizes. These new techniques provide challenges in terms of beam
dosimetry someone is concerned fields less than 4cm in diameter, and the accuracy to which beam algorithms can model these systems is decidedly
dependent on the measured scantling input materials. IMRT also involves dynamic multileaf collimator (MLC) or ’step and shoot’
techniques that provide photon fluences that vary according to the radiotherapy dosimetry requirements of the tumour target
and anatomical organs at risk.
Particle Physics and Astronomy Research Council (PPARC)
http://www.pparc.ac.uk
Polaris House
North Big name Avenue
Swindon
Wiltshire
SN2 1SZ
UK
Tel: +44(0)1793 442000
Fax: +44(0)1793 442125
SOURCE: http://www.alphagalileo.org